Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Endo CEO Reveals Glimpse Of New Strategy: Highlights Generics Potential

This article was originally published in The Pink Sheet Daily

Executive Summary

During Endo’s first quarter sales and earnings call, new CEO Rajiv De Silva said his strategic review of the specialty pharma is still underway but offered investors some initial thoughts on his plans for the company.

You may also be interested in...



Endo’s Revamp Signals Reversal From Previous CEO’s Diversification Strategy

Formerly of Valeant, new CEO Rajiv De Silva appears to be reworking Endo in the mold of his previous company, with plans to divest its early-stage pipeline and focus on growth through business development.

Surgical Mesh And Sling Devices Must Undergo Post-Market Studies

FDA sends post-market study orders to 33 manufacturers of urogynecologic surgical mesh used for pelvic organ prolapse and to seven makers of single-incision mini-slings used for stress urinary incontinence.

Endo Diversifies Further With Purchase Of Qualitest for $1.2 Billion

By buying the sixth-largest generics firm in the U.S. Endo gets what it says is critical mass in the U.S. generics market and significant domestic manufacturing capability.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel